This website uses necessary cookies for its operation and optional cookies to improve the experience, personalize content, and analyze usage. For more information, please refer to our Privacy Policy and Cookie Policy.

ADVERSE EVENT REPORTING

At humanova, we identify, collect reports of, assess, and prevent adverse events associated with the use of our products to safeguard patient safety and continuously monitor our products’ benefit–risk profiles.

Frequently Asked Questions
1 What Is an Adverse Event?

Any undesirable clinical occurrence in a patient who has been administered a product—whether a medicinal product, medical device, or cosmetic—which does not necessarily have a causal relationship with its use.1 In this context, the key consideration is the temporal association, without any suspicion of a causal relationship.

2 What Is Pharmacovigilance?

The World Health Organization (WHO) defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding, and prevention of adverse events or any other health problem associated with medicines or vaccines.2

3 What Is Medical Device Vigilance?

The Pan American Health Organization (PAHO) defines technovigilance as a set of methods and observations used to detect adverse events during the use of a medical device that could harm the patient, the operator, or their surroundings. Problems, malfunctions, risks, or potential risks arising from the use of medical devices may be collectively referred to as adverse incidents.3

4 What Is Cosmetovigilance?

Cosmetovigilance is defined as the activity of collecting, assessing, and monitoring information concerning undesirable effects observed as a result of the normal or reasonably foreseeable use of cosmetic products, as well as implementing measures and disseminating information related to such effects.4

REFERENCES

  1. Uppsala Monitoring Centre. Glossary [Internet]. Uppsala: Uppsala Monitoring Centre; [citado 17 Jul 2026]. Disponible en: https://who-umc.org.
  2. World Health Organization. Pharmacovigilance [Internet]. Geneva: OMS; [cited July 17, 2026]. Available at: https://www.who.int.
  3. Pan American Health Organization. Good Pharmacovigilance Practices for the Americas [Internet]. Washington, D.C.: OPS; 2011 [cited July 17, 2026]. 78 p. (Red PARF Technical Document, No. 5). Available at: https://www.paho.org.
  4. Spanish Agency for Medicines and Medical Devices. Cosmetovigilance [Internet]. Madrid: AEMPS; 14 May 2025 [cited July 17, 2026]. Available at: https://www.aemps.gob.es.

Email Addresses and Telephone Numbers of Our Subsidiaries

  • humanova Brazil
    farmacovigilancia@farmarin.com.br
    +55 11 24028800 (extension 297)
  • humanova Chile
    farmacovigilancialsa@humanovalab.com
    +56 985 273520
  • humanova Colombia
    farmacoytecnovigilanciacol@humanovalab.com
    + 57 604 2044590
  • humanova Ecuador
    farmacovigilancia@medifarma.ec
    +59 3999117634
  • humanova Paraguay
    sidb@humanovalab.com
    +59 521 683883
  • humanova Peru
    farmacovigilancia@humanovalab.com / tecnovigilancia@humanovalab.com / cosmetovigilancia@humanovalab.com
    +51 1 332 6200 (extensions 5211/5230)
  • humanova Portugal
    farmacovigilancia@atral.pt
    +351 214278610
  • humanova Uruguay
    farmacovigilancia-uruguay@humanovalab.com
    +598 2215 2302 (extension 1301)
REPORT YOUR ADVERSE EVENT!

To report an adverse event related to any of our products, please contact us using the form below.


    Patient Data

    Sex (*)

    Adverse Event Description


    Product Data


    Notifier Data

    FFTE-237-01